MCID: LCL006
MIFTS: 61

Localized Scleroderma malady

Categories: Rare diseases, Skin diseases, Immune diseases, Neuronal diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Genetic diseases

Aliases & Classifications for Localized Scleroderma

Aliases & Descriptions for Localized Scleroderma:

Name: Localized Scleroderma 12 50 56 14 69
Morphea 12 50 52 69
Localized Fibrosing Scleroderma 50 56
Scleroderma, Circumscribed or Localized 12
Unspecified Circumscribed Scleroderma 12
Localized Scleroderma [ambiguous] 12
Circumscribed Scleroderma Nos 12
Circumscribed Scleroderma 12
Scleroderma, Localized 50
Localised Morphoea 12
Localized Morphea 12

Characteristics:

Orphanet epidemiological data:

56
localized scleroderma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8472
ICD10 33 L94.0
ICD9CM 35 701.0
MeSH 42 D012594
NCIt 47 C72069
Orphanet 56 ORPHA90289
UMLS via Orphanet 70 C0036420
ICD10 via Orphanet 34 L94.0
MESH via Orphanet 43 D012594
UMLS 69 C0036420

Summaries for Localized Scleroderma

NIH Rare Diseases : 50 localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. collagen is a protein normally present in our skin that provides structural support. however, when too much collagen is made, the skin becomes stiff and hard. localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. internal organs are not affected by localized scleroderma, and localized scleroderma can never progress to the systemic form of the disease. often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. for some people, localized scleroderma is serious and disabling. there are two generally recognized types of localized scleroderma: morphea and linear.   last updated: 4/3/2012

MalaCards based summary : Localized Scleroderma, also known as morphea, is related to calcinosis and rheumatoid arthritis, and has symptoms including arthralgia, myalgia and lipoatrophy. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Vaccines and Bosentan have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and skeletal muscle, and related phenotypes are cellular and growth/size/body region

Wikipedia : 71 Morphea, also called localized scleroderma or circumscribed scleroderma, is a form of scleroderma that... more...

Related Diseases for Localized Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive Localized Scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 156)
id Related Disease Score Top Affiliating Genes
1 calcinosis 29.3 CTGF IL6 TGFB1 TNF
2 rheumatoid arthritis 29.0 IL6 MMP1 MMP13 TGFB1 TNF
3 systemic scleroderma 11.6
4 linear scleroderma 11.3
5 atrophoderma of pierini and pasini 11.0
6 diffuse large b-cell lymphoma 10.3 MMP1 TGFB1
7 noonan syndrome 4 10.3 MMP1 TGFB1
8 chronic diarrhea due to guanylate cyclase 2c overactivity 10.2 DCN MMP1
9 miliaria 10.2 CTGF TGFB1
10 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 IL6 TNF
11 bilateral parasagittal parieto-occipital polymicrogyria 10.2 TGFB1 TNF
12 stevens-johnson syndrome/toxic epidermal necrolysis 10.2 BMP6 DCN TGFB1
13 apert syndrome 10.2 BMP6 DCN TGFB1
14 leber congenital amaurosis 10.2 MMP1 SMAD3 TGFB1
15 dyslexia 5 10.2 IL6 TNF
16 mass syndrome 10.2 BMP6 DCN TGFB1
17 geleophysic dysplasia 2 10.2 CTGF TGFB1
18 distal trisomy 14q 10.2 TGFB1 TNF
19 aortic atherosclerosis 10.2 IL6 TNF
20 degenerative disc disease 10.2 IL6 TNF
21 speech and communication disorders 10.2 BMP6 SMAD3 TGFB1
22 zika fever 10.1 CTGF MMP1 TGFB1
23 lubani-al saleh-teebi syndrome 10.1 DCN SMAD3 TGFB1
24 anhidrosis 10.1 BMP6 CTGF TGFB1
25 unilateral multicystic dysplastic kidney 10.1 IL6 TNF
26 thymic neuroendocrine carcinoma 10.1 IL6 TNF
27 atherosclerosis 10.1 IL6 SELE
28 swine influenza 10.1 IL6 TNF
29 acquired thrombocytopenia 10.1 IL6 MMP1 TNF
30 pulmonary valve insufficiency 10.1 CTGF SMAD3 TGFB1
31 drug dependence 10.1 IL6 TNF
32 autosomal recessive type iv ehlers-danlos syndrome 10.1 IL6 MMP1 TNF
33 anal paget's disease 10.1 IL6 TGFB1 TNF
34 preaxial polydactyly of fingers 10.1 IL6 TGFB1 TNF
35 hypoparathyroidism-retardation-dysmorphism syndrome 10.1 IL6 TGFB1 TNF
36 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.1 IL6 TGFB1 TNF
37 carotenemia 10.1 IL6 MMP1 TNF
38 reynolds syndrome 10.1
39 acute necrotizing encephalitis 10.1 CTGF SMAD3 TGFB1
40 transient tic disorder 10.1 BMP6 IL6 TNF
41 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.1 SELE TNF
42 retinitis pigmentosa 51 10.1 IL6 MMP1 TNF
43 labyrinthitis 10.1 IL6 TGFB1 TNF
44 immunoglobulin g deficiency 10.1 IL6 TGFB1 TNF
45 slate pneumoconiosis 10.1 BMP6 TNF
46 myiasis 10.1 IL6 TGFB1 TNF
47 orthostatic proteinuria 10.1 BMP6 IL6 TNF
48 burns 10.1 IL6 TGFB1 TNF
49 red cell phospholipid defect with hemolysis 10.1 BMP6 IL6 TNF
50 baritosis 10.1 IL6 TGFB1 TNF

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic Scleroderma Vulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to Localized Scleroderma

Symptoms & Phenotypes for Localized Scleroderma

Human phenotypes related to Localized Scleroderma:

56 32 (show all 16)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 56 32 Occasional (29-5%) HP:0002829
2 myalgia 56 32 Occasional (29-5%) HP:0003326
3 lipoatrophy 56 32 Occasional (29-5%) HP:0100578
4 skeletal muscle atrophy 56 32 Frequent (79-30%) HP:0003202
5 split hand 56 32 Occasional (29-5%) HP:0001171
6 flexion contracture of toe 56 32 Occasional (29-5%) HP:0005830
7 hyperpigmentation of the skin 56 32 Very frequent (99-80%) HP:0000953
8 hypopigmentation of the skin 56 32 Very frequent (99-80%) HP:0001010
9 stiff skin 56 32 Very frequent (99-80%) HP:0030053
10 cigarette-paper scars 56 32 Very frequent (99-80%) HP:0001073
11 scarring alopecia of scalp 56 32 Occasional (29-5%) HP:0004552
12 hemiatrophy of lower limb 56 32 Occasional (29-5%) HP:0100557
13 hemiatrophy of upper limb 56 32 Occasional (29-5%) HP:0100558
14 flexion contracture 56 Occasional (29-5%)
15 hemiatrophy 56 Occasional (29-5%)
16 dermal atrophy 56 Very frequent (99-80%)

UMLS symptoms related to Localized Scleroderma:


exanthema, pruritus

MGI Mouse Phenotypes related to Localized Scleroderma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 CTGF DCN IL6 MMP13 SELE SMAD3
2 growth/size/body region MP:0005378 10.06 BMP6 CTGF DCN IL6 MMP13 SELE
3 cardiovascular system MP:0005385 10.02 SELE SMAD3 TGFB1 TNF CTGF IL6
4 homeostasis/metabolism MP:0005376 10.02 CTGF DCN IL6 MMP1 MMP13 SELE
5 integument MP:0010771 9.92 CTGF DCN IL6 MMP13 SELE SMAD3
6 digestive/alimentary MP:0005381 9.91 CTGF DCN IL6 SMAD3 TGFB1 TNF
7 neoplasm MP:0002006 9.73 DCN IL6 MMP1 SMAD3 TGFB1 TNF
8 respiratory system MP:0005388 9.63 TGFB1 TNF CTGF DCN IL6 SELE
9 skeleton MP:0005390 9.56 TGFB1 TNF BMP6 CTGF DCN IL6
10 vision/eye MP:0005391 9.17 CTGF DCN IL6 SELE SMAD3 TGFB1

Drugs & Therapeutics for Localized Scleroderma

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865
3
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
6
Acetylcholine Approved Phase 3 51-84-3 187
7
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
8
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
9
Lenograstim Approved Phase 3 135968-09-1
10
Domperidone Approved, Investigational, Vet_approved Phase 3 57808-66-9 3151
11
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
12
Glucosamine Approved, Nutraceutical Phase 2, Phase 3 3416-24-8 439213
13 Sildenafil Citrate Phase 3 171599-83-0
14 Vasodilator Agents Phase 3,Phase 2
15 Endothelin Receptor Antagonists Phase 2, Phase 3
16 Phosphodiesterase 5 Inhibitors Phase 3
17 Phosphodiesterase Inhibitors Phase 3
18 Antihypertensive Agents Phase 2, Phase 3,Phase 1
19 Antirheumatic Agents Phase 3,Phase 2,Phase 1
20 Calcium, Dietary Phase 3,Phase 2,Phase 1
21 insulin Phase 3
22
Proton pump inhibitors Phase 3
23 interferons Phase 3,Phase 1
24 Alkylating Agents Phase 3,Phase 2,Phase 1
25 Chelating Agents Phase 3,Phase 2
26 Cholinergic Agents Phase 3
27 Adjuvants, Immunologic Phase 3
28 Gastrointestinal Agents Phase 3
29 Neuromuscular Agents Phase 3
30 Sodium Channel Blockers Phase 2, Phase 3
31 Coagulants Phase 3,Phase 1
32 Neurotransmitter Agents Phase 3
33
Alginic acid Phase 3 9005-32-7
34 Glucuronyl glucosamine glycan sulfate Phase 2, Phase 3
35 Hemostatics Phase 3,Phase 1
36 Anesthetics Phase 2, Phase 3
37 Diuretics, Potassium Sparing Phase 2, Phase 3
38 Peripheral Nervous System Agents Phase 2, Phase 3, Phase 1
39 Anesthetics, Local Phase 2, Phase 3
40 Dopamine Agents Phase 3
41 Dopamine Antagonists Phase 3
42 Antacids Phase 3
43 Pharmaceutical Solutions Phase 2, Phase 3
44 Anti-Arrhythmia Agents Phase 2, Phase 3
45 Hypoglycemic Agents Phase 2, Phase 3
46 Hypolipidemic Agents Phase 2, Phase 3
47 abobotulinumtoxinA Phase 3
48 incobotulinumtoxinA Phase 3
49 onabotulinumtoxinA Phase 3
50 Immunosuppressive Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 79)
id Name Status NCT ID Phase
1 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3
3 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3
4 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3
5 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3
6 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3
7 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3
8 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3
9 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3
10 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3
11 Scleroderma Lung Disease Completed NCT00004563 Phase 3
12 Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Withdrawn NCT00230373 Phase 3
13 A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Unknown status NCT00936546 Phase 2
14 Zibotentan Better Renal Scleroderma Outcome Study Unknown status NCT02047708 Phase 2
15 Efficacy and Safety of Imatinib in Scleroderma Completed NCT00479934 Phase 2
16 Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix Completed NCT00129428 Phase 1, Phase 2
17 Effect of Bosentan in Scleroderma Renal Crisis Completed NCT01241383 Phase 2
18 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2
19 Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis Completed NCT00764309 Phase 1, Phase 2
20 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma Completed NCT00278525 Phase 2
21 Oral Type I Collagen for Relieving Scleroderma Completed NCT00005675 Phase 2
22 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Completed NCT00442611 Phase 1, Phase 2
23 Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers Completed NCT02801305 Phase 2
24 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed NCT00883129 Phase 2
25 Psychological Treatments for Scleroderma Completed NCT00007267 Phase 2
26 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease Completed NCT01559129 Phase 2
27 Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne Recruiting NCT03076320 Phase 1, Phase 2
28 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2
29 Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Recruiting NCT02213705 Phase 1, Phase 2
30 Riociguat in Scleroderma Associated Digital Ulcers Recruiting NCT02915835 Phase 2
31 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Recruiting NCT02682511 Phase 2
32 IL1-TRAP, Rilonacept, in Systemic Sclerosis Active, not recruiting NCT01538719 Phase 1, Phase 2
33 Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma Not yet recruiting NCT03035188 Phase 2
34 Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Terminated NCT01545427 Phase 2
35 Placebo Controlled Trial of Bosentan in Scleroderma Patients Terminated NCT00377455 Phase 2
36 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Withdrawn NCT01918904 Phase 2
37 A Study of the Safety and Tolerability of MEDI-551 in Scleroderma Completed NCT00946699 Phase 1
38 A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Completed NCT00930683 Phase 1
39 Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma Recruiting NCT02837549 Phase 1
40 Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma Recruiting NCT02426229 Phase 1
41 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Terminated NCT00040651 Phase 1
42 Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea Withdrawn NCT02680717 Phase 1
43 Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Unknown status NCT02002897
44 Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Unknown status NCT01799174
45 Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples Unknown status NCT01553890
46 Prevention and Treatment of Digital Ulcers in Systemic Sclerosis Unknown status NCT01836263
47 Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. Completed NCT00812188
48 The CARRA Registry Completed NCT01697254
49 UVA1 Light for Treatment of Scleroderma and Similar Conditions Completed NCT00476801
50 Morbidity and Mortality Follow Up for the Scleroderma Lung Study Completed NCT01762449

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

Anatomical Context for Localized Scleroderma

MalaCards organs/tissues related to Localized Scleroderma:

39
Skin, Breast, Skeletal Muscle, Bone, Testes, Bone Marrow, Brain

Publications for Localized Scleroderma

Articles related to Localized Scleroderma:

(show top 50) (show all 369)
id Title Authors Year
1
Musculoskeletal MRI findings of juvenile localized scleroderma. ( 28091699 )
2017
2
Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. ( 28271552 )
2017
3
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. ( 28461535 )
2017
4
Quantitative Assessment of Skin Stiffness in Localized Scleroderma Using Ultrasound Shear-Wave Elastography. ( 28457631 )
2017
5
The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity. ( 27943304 )
2017
6
Correlation of clinical tools to determine activity of localized scleroderma in paediatric patients. ( 26138783 )
2016
7
Measurement of transepidermal water loss in localized scleroderma. ( 26970329 )
2016
8
Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma. ( 26983450 )
2016
9
Is Localized Scleroderma Caused by Borrelia burgdorferi? ( 27387068 )
2016
10
Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma. ( 26985179 )
2016
11
Localized scleroderma en coup de sabre in the Neurology Clinic. ( 27456882 )
2016
12
Localized Scleroderma: A Clinical Review. ( 27604889 )
2016
13
Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma:A a clinical and immunohistochemical randomized controlled study. ( 27510285 )
2016
14
Lichen sclerosus associated with localized scleroderma: dermoscopy contribution. ( 27579757 )
2016
15
Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations? ( 27693175 )
2016
16
Oxidative stress parameters in localized scleroderma patients. ( 27591994 )
2016
17
Neurological abnormalities in localized scleroderma of the face and head: a case series study for evaluation of imaging findings and clinical course. ( 27700194 )
2016
18
Mild Cognitive Impairment as a single sign of brain hemiatrophy in patient with Localized Scleroderma and Parry-Romberg Syndrome. ( 27154452 )
2016
19
Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. ( 26577237 )
2016
20
BILATERAL CHOROIDAL EXCAVATION IN JUVENILE LOCALIZED SCLERODERMA. ( 27533641 )
2016
21
A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. ( 27401109 )
2016
22
Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate. ( 26582717 )
2016
23
German guidelines for the diagnosis and therapy of localized scleroderma. ( 26819124 )
2016
24
Lupus erythematosus and localized scleroderma coexistent at the same sites: a rare presentation of overlap syndrome of connective-tissue diseases. ( 27274545 )
2016
25
Predictors of Longitudinal Quality of Life in Pediatric Localized Scleroderma. ( 27696700 )
2016
26
A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. ( 26161155 )
2015
27
Durometry as an Outcome Measure in Juvenile Localized Scleroderma. ( 26302039 )
2015
28
Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma. ( 25582037 )
2015
29
Systemic involvement in localized scleroderma/morphea. ( 26321403 )
2015
30
Localized Scleroderma of Lower Extremities:Clinical and Magnetic Resonance Imaging Features. ( 26564453 )
2015
31
Localized scleroderma: clinical spectrum and therapeutic update. ( 25672301 )
2015
32
Juvenile localized scleroderma with port wine stain: coincidental or possible common pathogenetic association. ( 25814757 )
2015
33
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. ( 26254121 )
2015
34
Localized Scleroderma Presenting as Port-wine Stains: Report of Two Cases and a Literature Review. ( 25791763 )
2015
35
The efficacy of dantrolene sodium for muscle cramps in patients with localized scleroderma. ( 26559172 )
2015
36
Recurrence rates in localized scleroderma (morphoea). ( 25776242 )
2015
37
Successful autologous hematopoietic stem cell transplantation for a patient with rapidly progressive localized scleroderma. ( 25923607 )
2015
38
Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. ( 25888470 )
2015
39
Localized scleroderma and regional inflammatory myopathy. ( 24569141 )
2014
40
United Kingdom survey of current management of juvenile localized scleroderma. ( 24850875 )
2014
41
A rare case of acquired partial lipodystrophy (Barraquer-Simons syndrome) with localized scleroderma. ( 23675994 )
2014
42
A Patient with Localized Scleroderma Successfully Treated with Etretinate. ( 25408646 )
2014
43
Parry Romberg syndrome with localized scleroderma: A case report. ( 25136439 )
2014
44
Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with pediatric or adult-onset disease. ( 25381928 )
2014
45
Down-regulation of microRNA-196a in the sera and involved skin of localized scleroderma patients. ( 25152444 )
2014
46
Pirfenidone gel in patients with localized scleroderma: a phase II study. ( 25533576 )
2014
47
Localized scleroderma variants: pharmacologic implications. ( 22905721 )
2014
48
Lipomatosis of the mons pubis secondary to localized scleroderma (Morphea): first report of surgical management. ( 25370577 )
2014
49
Co-existence of Lichen Sclerosus and Localized Scleroderma in Female Monozygotic Twins. ( 24841519 )
2014
50
Recurrent myelitis in localized scleroderma. ( 25459261 )
2014

Variations for Localized Scleroderma

Expression for Localized Scleroderma

Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for Localized Scleroderma

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 BMP6 CTGF IL6 MMP1 MMP13 SMAD3
2
Show member pathways
13.43 BMP6 CTGF IL6 SMAD3 TGFB1 TNF
3
Show member pathways
13.17 BMP6 CTGF IL6 SMAD3 TGFB1 TNF
4
Show member pathways
12.66 DCN MMP1 MMP13 TGFB1
5 12.58 IL6 MMP1 SMAD3 TGFB1
6
Show member pathways
12.57 BMP6 CTGF IL6 TGFB1 TNF
7
Show member pathways
12.5 IL6 SMAD3 TGFB1 TNF
8 12.33 IL6 SMAD3 TGFB1 TNF
9
Show member pathways
12.22 IL6 MMP1 MMP13 TNF
10 12.16 BMP6 SMAD3 TGFB1
11
Show member pathways
12.15 MMP1 SELE TGFB1
12 12.15 IL6 TGFB1 TNF
13
Show member pathways
12.12 IL6 TGFB1 TNF
14
Show member pathways
12.04 IL6 SMAD3 TGFB1
15 12.04 BMP6 CTGF SMAD3 TGFB1
16
Show member pathways
12.01 IL6 SMAD3 TGFB1
17 11.99 MMP1 SMAD3 TGFB1
18 11.94 IL6 MMP1 SMAD3 TGFB1 TNF
19 11.93 IL6 TGFB1 TNF
20 11.92 IL6 SMAD3 TGFB1 TNF
21 11.88 IL6 SELE TNF
22
Show member pathways
11.87 IL6 TGFB1 TNF
23 11.86 IL6 SMAD3 TGFB1
24
Show member pathways
11.84 IL6 SMAD3 TGFB1
25 11.84 IL6 MMP1 TGFB1 TNF
26
Show member pathways
11.82 MMP1 MMP13 TNF
27 11.8 IL6 TGFB1 TNF
28
Show member pathways
11.78 IL6 SMAD3 TGFB1
29 11.74 BMP6 DCN IL6 TGFB1
30 11.72 IL6 MMP1 SELE
31 11.69 IL6 MMP1 TGFB1 TNF
32 11.68 IL6 TGFB1 TNF
33 11.63 BMP6 CTGF IL6 TGFB1
34 11.63 IL6 TGFB1 TNF
35 11.62 BMP6 SMAD3 TGFB1
36 11.59 BMP6 MMP13 TGFB1
37 11.54 SMAD3 TGFB1 TNF
38 11.5 CTGF IL6 TGFB1 TNF
39 11.47 CTGF SMAD3 TGFB1
40
Show member pathways
11.47 IL6 MMP1 SELE TNF
41 11.43 CTGF IL6 TNF
42
Show member pathways
11.41 SMAD3 TGFB1
43 11.4 IL6 SMAD3 TNF
44 11.35 IL6 SELE SMAD3 TGFB1 TNF
45 11.27 IL6 MMP1 SMAD3 TGFB1
46 11.26 IL6 SELE TNF
47 11.23 DCN IL6 MMP1
48 11.16 IL6 TGFB1 TNF
49 11.15 IL6 SELE TGFB1 TNF
50 11.11 CTGF SMAD3

GO Terms for Localized Scleroderma

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 BMP6 CTGF DCN DEFB1 IL6 MMP1
2 extracellular matrix GO:0031012 9.56 DCN MMP1 MMP13 TGFB1
3 proteinaceous extracellular matrix GO:0005578 9.55 CTGF DCN MMP1 MMP13 TGFB1
4 Golgi lumen GO:0005796 9.5 DCN DEFB1 TGFB1
5 extracellular space GO:0005615 9.28 BMP6 CTGF DCN DEFB1 IL6 MMP13

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 48)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.96 BMP6 DEFB1 IL6 SMAD3 TNF
2 negative regulation of gene expression GO:0010629 9.87 CTGF TGFB1 TNF
3 leukocyte migration GO:0050900 9.87 MMP1 SELE TGFB1 TNF
4 positive regulation of protein phosphorylation GO:0001934 9.86 CTGF TGFB1 TNF
5 response to organic cyclic compound GO:0014070 9.85 CTGF IL6 TGFB1
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 IL6 TGFB1 TNF
7 positive regulation of protein kinase B signaling GO:0051897 9.82 IL6 TGFB1 TNF
8 extracellular matrix disassembly GO:0022617 9.81 DCN MMP1 MMP13
9 response to wounding GO:0009611 9.8 CTGF IL6 TGFB1
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 IL6 TGFB1 TNF
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 CTGF IL6 TGFB1 TNF
12 inflammatory response GO:0006954 9.8 BMP6 IL6 SELE TGFB1 TNF
13 response to glucocorticoid GO:0051384 9.79 BMP6 IL6 TNF
14 defense response to Gram-positive bacterium GO:0050830 9.79 DEFB1 IL6 TNF
15 aging GO:0007568 9.78 CTGF DCN IL6 TGFB1
16 positive regulation of epithelial cell proliferation GO:0050679 9.77 BMP6 IL6 TGFB1
17 SMAD protein signal transduction GO:0060395 9.77 BMP6 SMAD3 TGFB1
18 T cell activation GO:0042110 9.72 IL6 SMAD3 TGFB1
19 protein import into nucleus, translocation GO:0000060 9.7 TGFB1 TNF
20 endochondral ossification GO:0001958 9.7 BMP6 MMP13
21 positive regulation of collagen biosynthetic process GO:0032967 9.7 CTGF TGFB1
22 positive regulation of protein complex assembly GO:0031334 9.69 TGFB1 TNF
23 cell-cell junction organization GO:0045216 9.69 SMAD3 TGFB1
24 negative regulation of myoblast differentiation GO:0045662 9.68 TGFB1 TNF
25 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 9.68 SMAD3 TGFB1
26 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.68 SMAD3 TGFB1
27 positive regulation of chondrocyte differentiation GO:0032332 9.68 BMP6 SMAD3
28 positive regulation of chemokine production GO:0032722 9.67 IL6 TNF
29 leukocyte tethering or rolling GO:0050901 9.66 SELE TNF
30 acute inflammatory response GO:0002526 9.66 DEFB1 IL6
31 lens fiber cell differentiation GO:0070306 9.65 SMAD3 TGFB1
32 positive regulation of SMAD protein import into nucleus GO:0060391 9.65 BMP6 TGFB1
33 negative regulation of lipid storage GO:0010888 9.65 IL6 TNF
34 positive regulation of gene expression GO:0010628 9.65 CTGF IL6 SMAD3 TGFB1 TNF
35 SMAD protein complex assembly GO:0007183 9.64 SMAD3 TGFB1
36 positive regulation of nitric oxide biosynthetic process GO:0045429 9.63 IL6 SMAD3 TNF
37 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.61 IL6 TNF
38 extrinsic apoptotic signaling pathway GO:0097191 9.61 SMAD3 TGFB1 TNF
39 regulation of striated muscle tissue development GO:0016202 9.58 SMAD3 TGFB1
40 regulation of binding GO:0051098 9.54 SMAD3 TGFB1
41 positive regulation of bone mineralization GO:0030501 9.54 BMP6 SMAD3 TGFB1
42 positive regulation of extracellular matrix assembly GO:1901203 9.52 SMAD3 TGFB1
43 positive regulation of mononuclear cell migration GO:0071677 9.51 TGFB1 TNF
44 negative regulation of mitotic cell cycle GO:0045930 9.33 SMAD3 TGFB1 TNF
45 evasion or tolerance of host defenses by virus GO:0019049 9.32 SMAD3 TGFB1
46 wound healing GO:0042060 9.26 DCN IL6 SMAD3 TGFB1
47 negative regulation of fat cell differentiation GO:0045599 8.92 IL6 SMAD3 TGFB1 TNF
48 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.06 BMP6 DCN IL6 SMAD3 TGFB1 TNF

Molecular functions related to Localized Scleroderma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 BMP6 IL6 TGFB1 TNF
2 collagen binding GO:0005518 9.43 DCN MMP13 SMAD3
3 transforming growth factor beta receptor binding GO:0005160 9.13 BMP6 SMAD3 TGFB1
4 growth factor activity GO:0008083 8.92 BMP6 CTGF IL6 TGFB1

Sources for Localized Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....